Skip to main content

Table 4 Adverse events and serious adverse events

From: A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults

Number of subjects (% of treatment group) 100 mg IV Ibuprofen 200 mg IV Ibuprofen 400 mg IV Ibuprofen Placebo
Subjects experiencing no AEs 4 13% 5 17% 8 26% 3 11%
Subjects experiencing any AEs (including SAEs) 27 87% 25 83% 23 74% 25 89%
Subjects experiencing SAEs (including death) 6 19% 5 17% 4 13% 4 14%
Patient deaths 1 3% 2 7% 2 6% 1 4%
Total subjects 31   30   31   28